...
首页> 外文期刊>In vivo. >Inhibitory Action of Levocetirizine on the Production of Eosinophil Chemoattractants RANTES and Eotaxin In Vitro and In Vivo
【24h】

Inhibitory Action of Levocetirizine on the Production of Eosinophil Chemoattractants RANTES and Eotaxin In Vitro and In Vivo

机译:左西替利嗪在体外和体内对嗜酸性粒细胞趋化因子RANTES和嗜酸性粒细胞趋化因子产生的抑制作用

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Eosinophils are well known to play essential roles in the development and maintenance of allergic diseases. However, the influence of histamine H1 receptor antagonists on eosinophil functions, especially chemokine production, are not well-defined. Therefore, in the present study, we examined the influence of histamine H1 receptor antagonist on chemokine production by eosinophils through the use of levocetirizine in vitro and in vivo. Eosinophils prepared from mice were stimulated with specific antigens in the presence of different concentrations of levocetirizine. After 24 h, regulated on activation normal T cell expressed and secreted (RANTES) and eotaxin levels in culture supernatants were measured by enzyme-linked immunosorbent assay (ELISA). Patients with Japanese cedar pollinosis were treated with 5 mg levocetirizine once a day for four weeks during the pollen season (February 2012 to April 2012). RANTES and eotaxin levels in nasal secretions were also examined by ELISA. The addition of levocetirizine to eosinophil cultures caused a dose-dependent decrease in the ability of cells to produce RANTES and eotaxin in response to antigen stimulation, and the minimum concentration that caused a significant decrease was 0.05 M. Although cetirizine also exerted suppressive effects on the production of RANTES and eotaxin by eosinophils, the minimum concentration that caused significant suppression was 0.15 M, which was three-times higher than that of levocetirizine. Oral administration of levocetirizine for four weeks also reduced RANTES and eotaxin levels in nasal secretions from patients with pollinosis, along with attenuation of clinical symptoms. The ability of levocetirizine to reduce RANTES and eotaxin levels may account, at least in part, for the clinical efficacy of the agent for allergic disorders, including allergic rhinitis.
机译:众所周知,嗜酸性粒细胞在过敏性疾病的发展和维持中起着至关重要的作用。但是,组胺H1受体拮抗剂对嗜酸性粒细胞功能,特别是趋化因子产生的影响尚不清楚。因此,在本研究中,我们通过体内和体外使用左西替利嗪检查了组胺H1受体拮抗剂对嗜酸性粒细胞趋化因子产生的影响。在不同浓度的左西替利嗪存在下,用特异性抗原刺激从小鼠制备的嗜酸性粒细胞。 24小时后,调节活化的正常T细胞的表达和分泌(RANTES),并通过酶联免疫吸附测定(ELISA)测量培养上清液中的趋化因子水平。在花粉季节(2012年2月至2012年4月),日本雪松花粉病患者每天接受5 mg左西替利嗪治疗,持续4周。还通过ELISA检查了鼻分泌物中的RANTES和嗜酸性粒细胞趋化因子水平。向嗜酸性粒细胞培养物中加入左西替利嗪会导致细胞响应抗原刺激而产生RANTES和嗜酸性粒细胞趋化因子的能力呈剂量依赖性下降,而引起显着下降的最小浓度为0.05M。尽管西替利嗪也对嗜酸性粒细胞产生RANTES和嗜酸性粒细胞趋化因子时,引起显着抑制的最低浓度为0.15 M,比左西替利嗪高三倍。口服给予左西替利嗪四周还降低了花粉病患者鼻分泌物中的RANTES和嗜酸性粒细胞趋化因子水平,并减轻了临床症状。左西替利嗪降低RANTES和嗜酸细胞活化趋化因子水平的能力可能至少部分解释了该药物对过敏性疾病(包括过敏性鼻炎)的临床疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号